

**AREA PRESCRIBING COMMITTEE – ACTION LIST 11<sup>th</sup> OCTOBER 2018**

| Action Reference    | Minute Reference | ACTION  | OWNER | FURTHER COMMENTS  | TARGET DATE | STATUS (R/A/Clear) |
|---------------------|------------------|---|-------|---|-------------|--------------------|
| <b>ACTIONS 2017</b> |                  |   |       |   |             |                    |
| 15/17               | 28/17            | <b>Woundcare review</b> – Cumbria RDTC report for Wound care to be forwarded to the Tissue Viability group for review and explanation of dressing cost and choice and proposals for reducing spend and/or volume<br>Tissue Viability group to audit the use of antibiotic and honey dressings for clinical appropriateness.   | HH    | Audit and results are due to be reviewed at the December 2018 APC meeting.  | 06.12.2018  | ONGOING            |
| 53/17               | 89/17            | <b>NTAG – Paliperidone long acting injection (Xepilon®) and Paliperidone 3 monthly injection ( Trevicta®) for schizophrenia</b> – Paliperidone 3 monthly injection ( Trevicta®) RECOMMENDED as per its licensed indications. – RED CPFT to update SCG alongside this recommendation.  | HH    | CPFT awaiting clear guidance until updating on how the SCG’s system will operate when we move across to the North of Tyne APC and Formulary.<br>ONGOING until decision is made. |             | ONGOING            |
| 72/17               | 116/17           | <b>Guidelines for the monitoring of IMD’s</b><br>Noted for information. This reference document to be used alongside the Shared Care Guideline updates for North Cumbria as they arise.   | PF    | PF to take forward with NCUHT   | 06.12.2018  | ONGOING            |
| <b>ACTIONS 2018</b> |                  |   |       |   |             |                    |
| 04/18               | 13/18            | <b>Metolazone and Ranolazine prescribing</b> — The guideline was brought back to the committee with the noted changes from previous meetings. The name of the guideline to be updated to “Prescribing guideline for Metolazone”. The updated document states that primary care will now perform the necessary blood tests for monitoring, due to the Heart Failure Nursing team not having the capacity. Noted that this could not happen in primary care so the nursing team will have to take on this task if the guideline is to be passed. Primary care will be happy to prescribe Metolazone | JF    | PU to inform Mr Ibrahim of the necessary changes.   | 06.12.2018  | ONGOING            |

|       |       |  |          |   |            |         |
|-------|-------|--|----------|---|------------|---------|
|       |       | once all the necessary tests have been completed and reviewed by secondary care.   |          |   |            |         |
| 08/18 | 17/18 | <b>NG89:</b> Venous thromboembolism in over 16's: reducing the risk of hospital-acquired DVT or PE – Noted – Secondary care to review prescribing policy in conjunction with pre-assessment team.  | JF       | Noted – Clive Graham NCUHT is now leading on this review within NCUHT. new protocol and local guideline to be written. JF to take over this action in BG absence.   | 06.12.2018 | ONGOING |
| 18/18 | 43/18 | <b>Colomycin nebulisers SCG</b> – Licensed product is now readily available for the treatment of adults with bronchiectasis so an Amber RAG rating with shared care is requested.  | JF       | BG to feedback to John Atkinson that a patient leaflet is required and also to confirm the patient review arrangements. The sundries needed on the SCG also to be reviewed to see what is exactly is required as these may not be available in primary care. JF to follow up.               | 06.12.2018 | ONGOING |
| 24/18 | 55/18 | <b>Transition to North of Tyne APC</b><br>Primary care and secondary care formulary review to be done and reviewed by all teams, HG to forward templates to both PF and HH for secondary care. Formulary review meeting to be held on the 14 <sup>th</sup> November to review the differences highlighted by the groups. | HG<br>JF | These can then be brought to the December 18 APC meeting for ratification.  | 06.12.2018 | ONGOING |
| 34/18 | 65/18 | <b>Sodium Valproate PREVENT programme</b> currently being rolled out across North Cumbria.   | HH       | HH has forwarded the data for North Cumbria to the Mental Health and Learning Disabilities lead within CPFT, this will be shared with the newly appointed Medicines Safety Officer covering both trusts. Item to kept on the agenda until we are aware all processes are suitably in place. | 06.12.2018 | ONGOING |
| 36/18 | 67/18 | <b>Midazolam 10mg/2ml availability at NCUHT</b> – Jo Thomas, Specialist Pharmacist Community Services, CPFT presented the committee with the paper outlining the request to have Midazolam 10mg/2ml injection as stock in certain clinical areas with NCUHT to treat palliative care patients. BG                        | JF       | BG and JF to feedback to the areas / wards where palliative care patients are to be treated to prescribe this drug for these patients earlier in their treatment pathway in the   | 06.12.2018 | ONGOING |

|       |       |   |          |   |            |         |
|-------|-------|---|----------|---|------------|---------|
|       |       | informed the committee that the patient safety panel within NCUHT decided that all Midazolam 10mg/2ml injection be supplied on a named basis only against a prescription chart, no stock to be held on any ward. This was due to a patient safety incident in the past.   |          | anticipation of its use.  |            |         |
| 37/18 | 68/18 | <b>Insulin passport</b> – The committee reviewed the insulin passport process and actual card and information sheets for patients, agreed that this would give patient choice across Cumbria, however it was noted that it would be the patient’s responsibility to carry this card / information with up to date dose regimes. | HH<br>HG | Further feedback to be brought to the October 2018 APC meeting from Cumbria Diabetes on how the passports will be issued to patients and from Community Pharmacies on their views of the scheme. HH to ask the diabetic champions within CPFT for their thoughts. | 06.12.2018 | ONGOING |
| 39/18 | 71/18 | <b>FreeStyle Libre supply</b> –   | JF<br>HH | AL and HH to work together to aid the supply of FreeStyle Libre from within the trust, with stock being held by the trust for direct supply to patients being one possibility.  | 06.12.2018 | ONGOING |
| 42/18 | 91/18 | <b>TA543</b> Tofacitinib - Treating active psoriatic arthritis after inadequate response to DMARDs.   | PU       | Blueteq form to be added.   | 06.12.2018 |         |
| 43/18 | 92/18 | <b>NG104:</b> Pancreatitis  | PU       | To be added to Prescription Pad.  | 06.12.2018 |         |
| 44/18 | 92/18 | <b>NG106:</b> Chronic heart failure in adults: diagnosis and management   | PU       | To be added to Prescription Pad.  | 06.12.2018 |         |
| 45/18 | 96/18 | <b>NTAG- Ferric Maltol – treatment of IDA in patients with IBD</b> – Recommended as an alternative option in patients with mild to moderate IDA with IBD who have been unable to tolerate at least two oral ferrous salts due to adverts effects  | PU       | AMBER – To be added to RAG list.  | 06.12.2018 |         |
| 46/18 | 97/18 | <b>NTAG- Ferric Maltol – treatment of IDA in patients without IBD</b> – Recommended as an alternative option in patients with mild to moderate IDA who have been unable to tolerate at least two oral ferrous salts due to adverts effects.   | PU       | AMBER – To be added to RAG list.  | 06.12.2018 |         |
| 47/18 | 98/18 | <b>NTAG – Lycra Garments for the management of cerebral palsy and other neurological and musculoskeletal conditions</b> – Not recommended   | PU       | BLACK – To be added to RAG list.  | 06.12.2018 |         |

|       |        |   |          |   |            |  |
|-------|--------|---|----------|---|------------|--|
| 48/18 | 100/18 | <b>RDTC report feedback – Gastro Intestinal</b> High cost and volume of alginates continues, this has been an ongoing project within primary care to reduce the volume of Gaviscon Advance prescribed.                  | PF       | PF to speak with ENT consultants within NCUHT regarding the current formulary choices     | 06.12.2018 |  |
| 49/18 | 102/18 | <b>RDTC report feedback – Bone Metabolism</b> Bisphosphonate prescribing volume has decreased but costs have increased due to the spend in Denosumab prescribing.   | PU       | PU to look at Denosumab prescribing to look at increase in patients and spend on epact 2. | 06.12.2018 |  |
| 50/18 | 103/18 | <b>Liothyronine prescribing guideline</b> – Green + North of Tyne - Noted – to be discussed at the formulary review meeting as to how this will be disseminated to secondary care and how prescribing will be approved. | AL<br>PF |   | 06.12.2018 |  |
| 51/18 | 104/18 | <b>NoT APC Branded Prescribing guideline</b> – Approved – Noted – to be added to Prescription Pad.  | PU       |   | 06.12.2018 |  |
| 52/18 | 106/18 | <b>NoT Denosumab Information leaflet</b> – Approved – Noted – Ruth O’Neil (NECS MO Pharmacist) to review current North Cumbria documents and update and remove any duplication.   | HG       |   | 06.12.2018 |  |
| 53/18 | 113/18 | <b>Roflumilast RAG rating review</b> — Mathew Lane, Respiratory Consultant, NCUHT requested the RAG rating of Roflumilast to be in line with the current NoT rating of Green +, APPROVED.                               | PU       | Current RAG rating to be updated to AMBER.  | 06.12.2018 |  |

|  |                                 |
|--|---------------------------------|
|  | New action from current meeting |
|  | Action over one meeting old     |
|  | Action over two meetings old    |